Abstract
To investigate the efficacy and safety of concurrent chemoradiotherapy with capecitabine or oxaliplatin in locally advanced (T3-4 / N + M0) rectal cancer. A total of 56 patients with rectal cancer after radical operation were randomly divided into group A: capecitabine + oxaliplatin concurrent chemoradiotherapy group (Cap-Oxa-CRT trial, 30 cases), group B: capecitabine concurrent chemoradiotherapy group (Cap-CRT trial as Control group, 26 cases), both groups were given pelvic radiotherapy DT50.4Gy/28f/6 weeks. The two groups received adjuvant chemotherapy after concurrent CRT. (1) The 3-year overall survival rate, 3-year local recurrence rate and 3-year distant metastasis rate were not significantly different between the two groups (P> 0.05). (2) The incidence of grade 1-2 acute toxicity in group A during concurrent CRT was significantly higher than that in group B, the difference was statistically significant (P <0.05). Grade 3 toxicities were not statistically significant between the two groups (P> 0.05). No grade 4 toxicity was found in both groups. The incidences of interrupted or suspend concurrent chemotherapy in both groups were 19.23% and 46.67%, respectively, P <0.05. The incidences of interruption or suspension of radiotherapy were 11.54% and 30% respectively (P> 0.05). The completion rate of adjuvant chemotherapy in group B was higher than that in group A, but the difference was not statistically significant (P> 0.05). In postoperative adjuvant chemotherapy, the incidence of bone marrow suppression in group A was higher than that in group B (P <0.05), and the incidence of non-hematologic adverse reactions was similar between the two groups. Capecitabine combined oxaliplatin concurrent CRT, and oxaliplatin concurrent CRT have a good effect for treatment of patients with locally advanced rectal cancer after radical resection of rectal cancer. However, group A failed to further improve the curative effect, and its grade 1-2 toxicity increased significantly.
Highlights
To investigate the efficacy and safety of concurrent chemoradiotherapy with capecitabine or oxaliplatin in locally advanced (T3-4/N + M0) rectal cancer
For esophageal cancer patients treated by oxaliplatin 120 mg/m2 intravenously on day 1, and capecitabine 1000 mg/m2 orally twice daily on days 1–14 in a 21-day cycle of therapy, nausea and vomiting occurred in 51.6% of patients, leukopenia and diarrhea in 50%, stomatitis in 39.1%, polyneuropathy and handfoot syndrome occurred in 37.5% of patients [11]
The purpose of this study was to investigate the safety and efficacy of combined chemotherapy of capecitabineoxaliplatin and oxaliplatin alone when concurrent radiotherapy was performed in patients after radical resection of locally advanced rectal cancer
Summary
To investigate the efficacy and safety of concurrent chemoradiotherapy with capecitabine or oxaliplatin in locally advanced (T3-4/N + M0) rectal cancer. Colorectal cancer (CRC) is the third most common malignancy and the fourth leading cause of cancer death in the world, there were approximately 1.4 million new cases and nearly 0.7 million deaths in 2012. Chen et al Cancer Cell Int (2018) 18:123 agents in the treatment of patients with advanced colorectal cancer. Researches on adjuvant chemotherapy combined with radiotherapy after radical resection of rectal cancer have rarely been reported. The purpose of this study was to investigate the safety and efficacy of combined chemotherapy of capecitabineoxaliplatin and oxaliplatin alone when concurrent radiotherapy was performed in patients after radical resection of locally advanced rectal cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
